Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor ImmunityAndrew A. Guirguis, Mark A. Dawson, Yaara Ofir-Rosenfeld et al.|Cancer Discovery|2023Cited by 114
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C. Widemann, Frank M. Balis, Eva Dombi et al.|Neuro-Oncology|2014Cited by 114
Data from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor ImmunityAndrew A. Guirguis, Mark A. Dawson, Yaara Ofir-Rosenfeld et al.|Unknown|2023Cited by 2
Table S1 from Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances anti-tumour immunityAndrew A. Guirguis, Mark A. Dawson, Yaara Ofir-Rosenfeld et al.|Unknown|2024Cited by 0
Figure S5 from Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances anti-tumour immunityAndrew A. Guirguis, Mark A. Dawson, Yaara Ofir-Rosenfeld et al.|Unknown|2024Cited by 0